CONATUS PHARMACEUTICALS INC. INVESTMENT AGREEMENTInvestment Agreement • March 16th, 2017 • Conatus Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Investment Agreement (this “Agreement”) is made as of December 19, 2016 by and among Conatus Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Novartis Pharma AG, a Swiss corporation (the “Investor”).
ContractConatus Pharmaceuticals Inc. • March 16th, 2017 • Pharmaceutical preparations • Delaware
THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE EVIDENCE REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
Option, Collaboration and License Agreement By And Between Novartis Pharma AG And Conatus Pharmaceuticals Inc.Option, Collaboration and License Agreement • March 16th, 2017 • Conatus Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This OPTION, COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made as of this 19 day of December, 2016 (“Execution Date”), by and between Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland (“Novartis”) and Conatus Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware, U.S.A. (“Conatus”). Novartis and Conatus are each referred to individually as a “Party” and together as the “Parties.”
